VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds


Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Go
Feedback
You are here: IndiaNotes >> Market Insights - 27 Apr 2016 >> Obsession with P/e Multiple - IndiaNotes.com Market Insights Newsletter
27 | April | 2016 To view mail in browser, please click here Follow us on LinkedIn
IndiaNotes.com - Market Insights...take informed decisions
Research your Stock   |    Technical Calls   |    Live Market Action   |    Archives   |    Join Xchange

Welcome to Market Insights.

Table of contents:

1. Obsession with P/e Multiple

2. Dynamic Levels recommend a mid-cap pharmaceuticals & life science scrip as multi-bagger

3. Nifty Elite: A periodical report from Elliott Wave Perspective

4. SKS Microfinance - Potential to move 100% in one year

5. Thyrocare Technologies IPO: What Are Analysts Saying?

If you like us, please rate us on Facebook.


 

Obsession with P/e Multiple

P/e ratio is the most commonly used valuation ratio to make sense of how expensive or cheap a stock is. The reason for its popularity is its simplicity; P/e of 20 means the business is available at a market capitalization which is 20 times its annual earnings, in other words the stock price is trading at 20 times its EPS.

Click here to read the detailed analysis by Stalwart Investment Advisors


Dynamic Levels recommend a mid-cap pharmaceuticals & life science scrip as multi-bagger
According to Dynamic Levels, the company enjoys the largest market share of India for our Acetic Anhydride and Ethyl Acetate for the last two decades. It is also the largest manufacturer of Choline Chloride in India. It is trading at a PE of 14.88 taking support of 380 levels.

Nifty Elite: A periodical report from Elliott Wave Perspective
According to HDFC Securities, Nifty is finding strong resistance at 7980 and there are couple of resistance placed over there. So to validate a bigger bullish structure, the index should surpass 7980. Overall till violation of 7980, Nifty is in retracement move of the last rise.


SKS Microfinance - Potential to move 100% in one year
According to Bonvista Financial Planners, investors who can wait for a year can start accumulating SKS Microfinance with a time frame of one year at current level placing stop-loss at 520, while positional traders can buy this stock at current level for a time frame of 2-3 months and add more quantity at lower level till 550 placing stop-loss at 540.

Thyrocare Technologies IPO: What Are Analysts Saying?
Thyrocare Technologies Ltd, one of the leading pan-India diagnostic chains, has come up an IPO aiming at achieving the benefits of listing the Equity Shares on the BSE and the NSE as well as to carry out the sale of up to 10,744,708 Equity Shares by the Selling Shareholders.

Featured Technical Call for today by 777 Stocks
Buy TEXMO Pipes @ 28 - 28.10 and DIAMOND Power @ 31.30 - 31.50
Get day to day calls and stock tips with our Technical Newsletter section - Follow this page on LinkedIn here

Ask an Expert - An answer to your question is just an e-mail away!
IndiaNotes.com's Ask an Expert section has been very popular among our audience and readers, particularly because of our experts on board like Stalwart Investment Advisors among others for the prompt and convincing solutions they offer.

One of our readers and an active investor had approached our experts seeking stocks in the IT or banking sector stocks for good short-term gains. Although Stalwart Investment Advisors are into long-term investing and not trading, they still had an encouraging and convincing solution for the said investor.

Readers are most welcome to post their questions to our experts on board and get their queries answered.


If you would like to contribute your content, get in touch with us at write@indianotes.com
Do write in at
indianotes.editor@gmail.com and give us your feedback!

 
Advertise with us  |   Write for us   |   Blog on Xchange  |   Archives  |   Feedback
 
Privacy Policy